Bassiony, Sarah;
Harrison, Claire N;
McLornan, Donal P;
(2020)
Evaluating the Safety, Efficacy, and Therapeutic Potential of Momelotinib in the Treatment of Intermediate/High-Risk Myelofibrosis: Evidence to Date.
Therapeutics and Clinical Risk Management
, 16
pp. 889-901.
10.2147/TCRM.S258704.
Preview |
PDF
Evaluating the Safety, Efficacy, and Therapeutic Potential of Momelotinib in the Treatment of IntermediateHigh-Risk Myelofib.pdf - Published Version Download (353kB) | Preview |
Abstract
Myelofibrosis is a heterogeneous disorder with regard to both molecular pathogenesis and clinical phenotype, ranging from an initial fairly indolent condition in some through to an aggressive and debilitating scenario with profound constitutional symptoms, cytopenia frequently requiring transfusional support, and massive splenomegaly. Many advances have been made within the therapeutic arena, and an increasing array of novel agents are now available for disease management. Within this review, we focus on the current and predicted role of the JAK inhibitor momelotinib (Sierra Oncology) in myelofibrosis, with an emphasis on clinical trial evaluation, drug efficacyand safety, and discuss the suggested place in the therapeutic paradigm of myelofibrosis in 2020 and beyond.
| Type: | Article |
|---|---|
| Title: | Evaluating the Safety, Efficacy, and Therapeutic Potential of Momelotinib in the Treatment of Intermediate/High-Risk Myelofibrosis: Evidence to Date |
| Location: | New Zealand |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.2147/TCRM.S258704 |
| Publisher version: | https://doi.org/10.2147/TCRM.S258704 |
| Language: | English |
| Additional information: | © 2020 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, 3.0) License (https://creativecommons.org/licenses/by-nc/3.0/). |
| Keywords: | myelofibrosis, JAK inhibitors, momelotinib |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Haematology |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10218295 |
Archive Staff Only
 |
View Item |
